Is FLGT or BDSX more profitable?

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -23.04% -3.24% -2.97% Biodesix -33.26% -2,101.40% -35.65%

Do analysts prefer BDSX or MCTA?

Biodesix presently has a consensus price target of $22.00, indicating a potential upside of 32.39%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BDSX or MCTA?

Charming Medical has lower revenue, but higher earnings than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 1.95 -$35.26M -$4.06 N/A Charming Medical N/A N/A N/A N/A N/A

Do analysts rate VMD or BDSX?

Biodesix has a consensus price target of $22.00, suggesting a potential upside of 32.39%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, VMD or BDSX?

Viemed Healthcare has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viemed Healthcare $270.28M 1.41 $14.93M $0.37 26.78 Biodesix $88.50M 1.95 -$35.26M -$4.06 N/A

Biodesix (BDSX) Competitors

$16.58 +0.48 (+2.99%)

As of 10:53 AM Eastern

Compare

BDSX vs. FLGT, MCTA, TOI, AIRS, and VMD

Should you buy Biodesix stock or one of its competitors? MarketBeat compares Biodesix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodesix include Fulgent Genetics (FLGT), Charming Medical (MCTA), Oncology Institute (TOI), AirSculpt Technologies (AIRS), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Fulgent Genetics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.67	-$60.51M	-$2.39	N/A
Biodesix	$88.50M	1.95	-$35.26M	-$4.06	N/A

In the previous week, Fulgent Genetics had 7 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for Fulgent Genetics and 0 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat Fulgent Genetics' score of 0.35 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulgent Genetics	Neutral
Biodesix	Very Positive

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Biodesix	-33.26%	-2,101.40%	-35.65%

Fulgent Genetics presently has a consensus target price of $27.00, indicating a potential upside of 42.25%. Biodesix has a consensus target price of $22.00, indicating a potential upside of 32.39%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Fulgent Genetics beats Biodesix on 10 of the 15 factors compared between the two stocks.

How does Biodesix compare to Charming Medical?

Biodesix (NASDAQ:BDSX) and Charming Medical (NASDAQ:MCTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Charming Medical has a net margin of 0.00% compared to Biodesix's net margin of -33.26%. Charming Medical's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Charming Medical	N/A	N/A	N/A

Biodesix presently has a consensus price target of $22.00, indicating a potential upside of 32.39%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Charming Medical had 3 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for Charming Medical and 0 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat Charming Medical's score of 0.48 indicating that Biodesix is being referred to more favorably in the media.

Company	Overall Sentiment
Biodesix	Very Positive
Charming Medical	Neutral

Charming Medical has lower revenue, but higher earnings than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.95	-$35.26M	-$4.06	N/A
Charming Medical	N/A	N/A	N/A	N/A	N/A

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Biodesix beats Charming Medical on 7 of the 11 factors compared between the two stocks.

How does Biodesix compare to Oncology Institute?

Biodesix (NASDAQ:BDSX) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Biodesix has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oncology Institute had 1 more articles in the media than Biodesix. MarketBeat recorded 1 mentions for Oncology Institute and 0 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat Oncology Institute's score of 0.93 indicating that Biodesix is being referred to more favorably in the media.

Company	Overall Sentiment
Biodesix	Very Positive
Oncology Institute	Positive

Oncology Institute has a net margin of -7.42% compared to Biodesix's net margin of -33.26%. Oncology Institute's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Oncology Institute	-7.42%	N/A	-24.68%

Biodesix currently has a consensus price target of $22.00, suggesting a potential upside of 32.39%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 48.78%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Biodesix has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.95	-$35.26M	-$4.06	N/A
Oncology Institute	$502.73M	0.93	-$60.61M	-$0.37	N/A

Summary

Oncology Institute beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Biodesix compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

AirSculpt Technologies has a net margin of -7.39% compared to Biodesix's net margin of -33.26%. AirSculpt Technologies' return on equity of -4.98% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.39%	-4.98%	-2.36%
Biodesix	-33.26%	-2,101.40%	-35.65%

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AirSculpt Technologies has higher revenue and earnings than Biodesix. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	2.67	-$11.67M	-$0.17	N/A
Biodesix	$88.50M	1.95	-$35.26M	-$4.06	N/A

AirSculpt Technologies has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

AirSculpt Technologies presently has a consensus target price of $4.50, indicating a potential downside of 21.79%. Biodesix has a consensus target price of $22.00, indicating a potential upside of 32.39%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, AirSculpt Technologies had 3 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for AirSculpt Technologies and 0 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat AirSculpt Technologies' score of 0.31 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
AirSculpt Technologies	Neutral
Biodesix	Very Positive

Summary

AirSculpt Technologies beats Biodesix on 11 of the 16 factors compared between the two stocks.

How does Biodesix compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Biodesix has a consensus price target of $22.00, suggesting a potential upside of 32.39%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Viemed Healthcare has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

In the previous week, Viemed Healthcare's average media sentiment score of 1.89 beat Biodesix's score of 1.87 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Viemed Healthcare	Very Positive
Biodesix	Very Positive

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 20.0% of Viemed Healthcare shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Viemed Healthcare has a net margin of 5.20% compared to Biodesix's net margin of -33.26%. Viemed Healthcare's return on equity of 10.52% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	5.20%	10.52%	7.60%
Biodesix	-33.26%	-2,101.40%	-35.65%

Viemed Healthcare has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.41	$14.93M	$0.37	26.78
Biodesix	$88.50M	1.95	-$35.26M	-$4.06	N/A

Summary

Viemed Healthcare beats Biodesix on 10 of the 15 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$172.13M	$8.75B	$6.42B	$12.34B
Dividend Yield	N/A	1.79%	2.69%	5.22%
P/E Ratio	-4.09	22.82	23.80	24.23
Price / Sales	1.95	21.70	527.67	119.15
Price / Cash	N/A	87.48	41.34	57.13
Price / Book	-53.60	5.80	9.99	6.74
Net Income	-$35.26M	$178.24M	$3.56B	$337.06M
7 Day Performance	3.70%	-1.66%	-1.18%	-0.13%
1 Month Performance	N/A	N/A	N/A	-1.62%
1 Year Performance	179.90%	4.18%	28.52%	33.25%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	3.6345 of 5 stars	$16.62 +3.2%	$22.00 +32.4%	+168.3%	$172.13M	$88.50M	N/A	220	Positive News
FLGT Fulgent Genetics	3.0998 of 5 stars	$17.11 flat	$27.00 +57.8%	-14.3%	$508.97M	$322.67M	N/A	1,315
MCTA Charming Medical	N/A	$29.36 flat	N/A	N/A	$497.21M	N/A	N/A	49	Gap Down High Trading Volume
TOI Oncology Institute	4.2313 of 5 stars	$4.59 flat	$7.00 +52.5%	+32.2%	$453.67M	$502.73M	N/A	660
AIRS AirSculpt Technologies	1.6072 of 5 stars	$5.33 flat	$4.50 -15.6%	+11.7%	$376.01M	$151.82M	N/A	240	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. FLGT, MCTA, TOI, AIRS, and VMD

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to Charming Medical?

Summary

How does Biodesix compare to Oncology Institute?

Summary

How does Biodesix compare to AirSculpt Technologies?

Summary

How does Biodesix compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. FLGT, MCTA, TOI, AIRS, and VMD

How does Biodesix compare to Fulgent Genetics?

Which has more risk & volatility, FLGT or BDSX?

Do institutionals & insiders believe in FLGT or BDSX?

Which has stronger valuation and earnings, FLGT or BDSX?

Does the media refer more to FLGT or BDSX?

Is FLGT or BDSX more profitable?

Do analysts rate FLGT or BDSX?

Summary

How does Biodesix compare to Charming Medical?

Is BDSX or MCTA more profitable?

Do analysts prefer BDSX or MCTA?

Does the media prefer BDSX or MCTA?

Which has higher earnings & valuation, BDSX or MCTA?

Do insiders & institutionals believe in BDSX or MCTA?

Summary

How does Biodesix compare to Oncology Institute?

Which has more volatility and risk, BDSX or TOI?

Do insiders & institutionals believe in BDSX or TOI?

Does the media refer more to BDSX or TOI?

Is BDSX or TOI more profitable?

Do analysts rate BDSX or TOI?

Which has better earnings & valuation, BDSX or TOI?

Summary

How does Biodesix compare to AirSculpt Technologies?

Is AIRS or BDSX more profitable?

Do insiders & institutionals have more ownership in AIRS or BDSX?

Which has higher earnings & valuation, AIRS or BDSX?

Which has more volatility and risk, AIRS or BDSX?

Do analysts recommend AIRS or BDSX?

Does the media favor AIRS or BDSX?

Summary

How does Biodesix compare to Viemed Healthcare?

Do analysts rate VMD or BDSX?

Which has more risk & volatility, VMD or BDSX?

Does the media prefer VMD or BDSX?

Do insiders & institutionals have more ownership in VMD or BDSX?

Is VMD or BDSX more profitable?

Which has stronger valuation & earnings, VMD or BDSX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools